Javascript must be enabled to continue!
Effect of Yangyin Shuxin Decoction on Exercise Capacity in Patients with Heart Failure with Normal Ejection Fraction: Rationale and Design of a Randomized Controlled Trial
View through CrossRef
Abstract
Background The incidence of heart failure with normal ejection fraction (HFNEF) is increasing yearly, accounting for approximately half of all heart failure cases. Even after standardized treatment, the patient's prognosis is not good. Therefore, it is necessary to explore new treatment methods for HFNEF. Yangyin Shuxin Decoction, a traditional Chinese medicine prescription from our clinical experience in the treatment of HFNEF, has a potential cardioprotective effect. Preliminary clinical trials have shown that this prescription can improve the quality of life of HFNEF. This prompted us to use more objective indicators to further evaluate whether Yangyin Shuxin Decoction can improve the exercise capacity in HENEF patients. Methods This is a single-center parallel randomized controlled trial. The 64 patients who met the inclusion criteria were from the Cardiovascular Clinic. They will be randomly assigned to the treatment group (Yangying Shuxin Decoction combined with standard treatment) or the control group (standard treatment) according to the ratio of 1:1. The course of treatment will be 2 weeks. Both groups were interviewed at the following time points: of at enrollment (V1), and week 2 (V2), week 4 (V3), week 8 (V4), and week 12 (V5) after enrollment. The primary indicator is the peak oxygen consumption(Peak VO2) of the cardiopulmonary exercise test (CPET). Secondary indicators include CPET indicators such as anaerobic threshold oxygen consumption, carbon dioxide ventilation equivalent slope, echocardiographic indicators such as the ratio of mitral peak velocity of early filling to early diastolic mitral annular velocity(E/e′), left atrial volume index (LAVI), left ventricular mass index (LVMI), the peak velocity of tricuspid regurgitation (TR), B-type natriuretic peptide (BNP), New York Heart Association (NYHA) cardiac function grading, and so on. These indicators will be used to evaluate the effect of Yangyin Shuxin Decoction on exercise capacity in patients with HFNEF. Discussion At present, it is unclear whether the exercise capacity can be maintained after long-term use of Yangyin Shuxin Decoction. In this study, we will evaluate whether Yangyin Shuxin Decoction can improve the exercise capacity and quality of life of patients with HFNEF. This will provide an objective basis for the therapeutic effect of traditional Chinese medicine on HFNEF.
Springer Science and Business Media LLC
Title: Effect of Yangyin Shuxin Decoction on Exercise Capacity in Patients with Heart Failure with Normal Ejection Fraction: Rationale and Design of a Randomized Controlled Trial
Description:
Abstract
Background The incidence of heart failure with normal ejection fraction (HFNEF) is increasing yearly, accounting for approximately half of all heart failure cases.
Even after standardized treatment, the patient's prognosis is not good.
Therefore, it is necessary to explore new treatment methods for HFNEF.
Yangyin Shuxin Decoction, a traditional Chinese medicine prescription from our clinical experience in the treatment of HFNEF, has a potential cardioprotective effect.
Preliminary clinical trials have shown that this prescription can improve the quality of life of HFNEF.
This prompted us to use more objective indicators to further evaluate whether Yangyin Shuxin Decoction can improve the exercise capacity in HENEF patients.
Methods This is a single-center parallel randomized controlled trial.
The 64 patients who met the inclusion criteria were from the Cardiovascular Clinic.
They will be randomly assigned to the treatment group (Yangying Shuxin Decoction combined with standard treatment) or the control group (standard treatment) according to the ratio of 1:1.
The course of treatment will be 2 weeks.
Both groups were interviewed at the following time points: of at enrollment (V1), and week 2 (V2), week 4 (V3), week 8 (V4), and week 12 (V5) after enrollment.
The primary indicator is the peak oxygen consumption(Peak VO2) of the cardiopulmonary exercise test (CPET).
Secondary indicators include CPET indicators such as anaerobic threshold oxygen consumption, carbon dioxide ventilation equivalent slope, echocardiographic indicators such as the ratio of mitral peak velocity of early filling to early diastolic mitral annular velocity(E/e′), left atrial volume index (LAVI), left ventricular mass index (LVMI), the peak velocity of tricuspid regurgitation (TR), B-type natriuretic peptide (BNP), New York Heart Association (NYHA) cardiac function grading, and so on.
These indicators will be used to evaluate the effect of Yangyin Shuxin Decoction on exercise capacity in patients with HFNEF.
Discussion At present, it is unclear whether the exercise capacity can be maintained after long-term use of Yangyin Shuxin Decoction.
In this study, we will evaluate whether Yangyin Shuxin Decoction can improve the exercise capacity and quality of life of patients with HFNEF.
This will provide an objective basis for the therapeutic effect of traditional Chinese medicine on HFNEF.
Related Results
Efficacy and Safety of Yangyin Shuxin Decoction—a Chinese Herbal Medicine Formula For Heart Failure with Preserved Ejection Fraction: A Randomized Controlled Trial
Efficacy and Safety of Yangyin Shuxin Decoction—a Chinese Herbal Medicine Formula For Heart Failure with Preserved Ejection Fraction: A Randomized Controlled Trial
Background. Heart failure with preserved ejection fraction (HFpEF) is a large subtype of heart failure (HF) characterized by exercise intolerance and reduced quality of life. Studi...
Frequency of Common Chromosomal Abnormalities in Patients with Idiopathic Acquired Aplastic Anemia
Frequency of Common Chromosomal Abnormalities in Patients with Idiopathic Acquired Aplastic Anemia
Objective: To determine the frequency of common chromosomal aberrations in local population idiopathic determine the frequency of common chromosomal aberrations in local population...
Empagliflozin in the Real World: Strengthening Heart Failure Care in Pakistan
Empagliflozin in the Real World: Strengthening Heart Failure Care in Pakistan
Heart failure with reduced ejection fraction (HFrEF) remains a major clinical challenge worldwide and is a pressing public health issue in Pakistan. Patients here often present at ...
Comorbidities and sex differences in chronic heart failure of ischemic etiology
Comorbidities and sex differences in chronic heart failure of ischemic etiology
Abstract
Background: Comorbidities and sex differences play a major role in chronic heart failure (CHF). However, it is unknown whether the prevalence of comorbidities diff...
GW24-e2123 Effect of Sini Decoction on the expression of Sirt-1 and eNOS system in EAhy926 cells injured by homocysteine
GW24-e2123 Effect of Sini Decoction on the expression of Sirt-1 and eNOS system in EAhy926 cells injured by homocysteine
Objectives
To detect the effect of Sini Decoction on the expression of Sirt-1 and eNOS in EAhy926 cell injured by homocysteine.
...
Prevalence of Iron Deficiency in Patients of Heart Failure with Reduced Ejection Fraction and Response to Injectable Iron Therapy- A Hospital Based Observational Study
Prevalence of Iron Deficiency in Patients of Heart Failure with Reduced Ejection Fraction and Response to Injectable Iron Therapy- A Hospital Based Observational Study
Aim of the Study: To estimate the prevalence of iron deficiency in patients of heart failure with reduced ejection fraction & response to injectable iron therapy in patients wi...
Left Ventricular Function in Hospitalized Geriatric Patients
Left Ventricular Function in Hospitalized Geriatric Patients
ABSTRACT:
Left ventricular ejection fraction was measured by gated wall motion in 62 patients, 75 years old or older, admitted to a Geriatric Acute Assessment War...
Emerging Evidence of IgG4-Related Disease in Pericarditis: A Systematic Review
Emerging Evidence of IgG4-Related Disease in Pericarditis: A Systematic Review
Abstract
Introduction
Immunoglobulin G4-related disease (IgG4-RD) is a recently identified immune-mediated condition that is debilitating and often overlooked. While IgG4-RD has be...

